ABIONYX Pharma SA (609.SG)
| Previous Close | 0.9720 |
| Open | 0.9650 |
| Bid | 0.9610 x 25000 |
| Ask | 1.0640 x 25000 |
| Day's Range | 0.9650 - 0.9840 |
| 52 Week Range | 0.8780 - 1.9060 |
| Volume | |
| Avg. Volume | 153 |
| Market Cap | 32.917M |
| Beta (5Y Monthly) | -0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, April 10, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX)
Business WireABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant
TOULOUSE, France & LAKELAND, Mich., March 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces a nearly €1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology.
Business WireABIONYX Pharma Announces Its 2023 Full-Year Financial Results
TOULOUSE, France & LAKELAND, Mich., March 11, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announced its 2023 full-year financial results as approved by the full Board of Directors and an update on the activity to date. The audit procedures on the consolidated financial statements have been completed. T
